Short communication · 28 Nov 2020
Conference abstractPublished 25 Aug 2021
Hyperkalemia: Present and Future
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hyperkalemia is a potentially serious medical condition in which elevated serum potassium levels can increase the risk of severe cardiac electrophysiology abnormalities (e.g., cardiac arrhythmias) and sudden death. Modulation of renin-angiotensin-aldosterone system (RAAS) in reducing disease progression and in improving the outcome in heart failure and chronic kidney disease is very well documented and is recommended in respective guidelines. Unfortunately, patients with heart failure and chronic kidney disease are at greater risk of hyperkalemia with RAAS inhibitors than those without these conditions. Prescribing of reninâ??angiotensin inhibitors and mineralocorticoid antagonists is often limited by occurrence of hyperkalemia and further, underutilization of these potentially beneficial medications in consistent with established guidelines is common due to perceived risk of hyperkalemia. Although, there are effective management strategies in the treatment of acute hyperkalemia, the long-term management of hyperkalemia often requires withdrawing or reducing the doses of drugs proven to improve the outcome in heart failure and chronic kidney disease and/or implementing severe and sometimes intolerable dietary potassium restrictions. Withdrawal of RAAS inhibitors leads to increased morbidity and mortality consequent to rapid disease progression resulting in incremental healthcare cost. On the contrary, hyperkalemia itself is associated with significant adverse clinical outcome and incremental financial burden. The presence of hyperkalemia is a big risk factor for all-cause mortality regardless of the kidney function and results in increased emergency department visits and hospitalizations with economic consequences. There is unmet need of long-term treatment strategies of hyperkalemia. The new potassium binders (patiromer and zirconium cyclosilicate) have extended novel treatment options of chronic hyperkalemia allowing the use of RAAS inhibitors.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 29 Oct 2016
Concordant VS. Discordant Xeno Cardiac Transplantation; The past, present and future trends
Conference abstract
Regenerative therapeutic approaches for kidney regeneration: Present and future
Case report · 2016
Life-Threatening Severe Hyperkalemia Presenting Electrocardiographic Changes
Case report · 2014
Predictors of Outcome in Patients Presenting with Moderate to Severe Hyperkalemia
More from this journal
The newest in Journal of Stem Cell Biology and Transplantation.
Short communication · 25 Sep 2022
Tissue remodeling of the adrenal gland, testis, visceral adipose tissue, liver during obesity
Short communication · 25 Sep 2022
Long experience in regenerative medicine
Short communication · 25 Sep 2022
From experimental research to clinical trial in the treatment of complications of radiotherapy by stem cells
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Biology and Transplantation
- SubjectGenetics & Molecular Biology
- SubjectSurgery
- BylineArticles whose byline prints “Rajesh Sherke”

